Terms: = Skin cancer AND PDCD1, CD279, PD-1, PD1, SLEB2, hPD-1, hPD-l, hSLE1
3092 results:
1. Systemic Scleroderma Induced by Nivolumab in Malignant Melanoma.
Loupret T; Boisseau R; Lopez JG; Bertin P; Vergne-Salle P
In Vivo; 2024; 38(3):1451-1453. PubMed ID: 38688588
[TBL] [Abstract] [Full Text] [Related]
2. Interferon-gamma signature as prognostic and predictive marker in macroscopic stage III melanoma.
Versluis JM; Blankenstein SA; Dimitriadis P; Wilmott JS; Elens R; Blokx WAM; van Houdt W; Menzies AM; Schrage YM; Wouters MWJM; Sanders J; Broeks A; Scolyer RA; Suijkerbuijk KPM; Long GV; Akkooi ACJV; Blank CU
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38677880
[TBL] [Abstract] [Full Text] [Related]
3. Intratumor injection of BCG Ag85A high-affinity peptides enhanced anti-tumor efficacy in PPD-positive melanoma.
Qin L; Zhang G; Wu Y; Yang Y; Zou Z
Cancer Immunol Immunother; 2024 Apr; 73(6):103. PubMed ID: 38630135
[TBL] [Abstract] [Full Text] [Related]
4. Polyomavirus-positive Merkel cell carcinoma: the beginning of the beginning.
Wong MK; Yee C
J Clin Invest; 2024 Apr; 134(8):. PubMed ID: 38618960
[TBL] [Abstract] [Full Text] [Related]
5. T antigen-specific CD8+ T cells associate with pd-1 blockade response in virus-positive Merkel cell carcinoma.
Hansen UK; Church CD; Carnaz Simões AM; Frej MS; Bentzen AK; Tvingsholm SA; Becker JC; Fling SP; Ramchurren N; Topalian SL; Nghiem PT; Hadrup SR
J Clin Invest; 2024 Jan; 134(8):. PubMed ID: 38618958
[TBL] [Abstract] [Full Text] [Related]
6. Melanoma neoantigen vaccines: Are we getting more personal now?
Latifyan S; Haanen JB
Med; 2024 Apr; 5(4):288-290. PubMed ID: 38614074
[TBL] [Abstract] [Full Text] [Related]
7. In Silico Transcriptomic Expression of MSR1 in Solid Tumors Is Associated with Responses to Anti-pd1 and Anti-CTLA4 Therapies.
Sanvicente A; Díaz-Tejeiro C; Nieto-Jiménez C; Paniagua-Herranz L; López Cade I; Balázs G; Moreno V; Pérez-Segura P; Calvo E; Ocaña A
Int J Mol Sci; 2024 Apr; 25(7):. PubMed ID: 38612803
[TBL] [Abstract] [Full Text] [Related]
8. Autologous human preclinical modeling of melanoma interpatient clinical responses to immunotherapeutics.
Phoon YP; Lopes JE; Pfannenstiel LW; Marcela Diaz-Montero C; Tian YF; Ernstoff MS; Funchain P; Ko JS; Winquist R; Losey HC; Melenhorst JJ; Gastman BR
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38604813
[TBL] [Abstract] [Full Text] [Related]
9. Oncolytic herpes simplex virus expressing IL-2 controls glioblastoma growth and improves survival.
Bommareddy PK; Wakimoto H; Martuza RL; Kaufman HL; Rabkin SD; Saha D
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38599661
[TBL] [Abstract] [Full Text] [Related]
10. Frequency and characteristics of immune-related thyroid adverse events in patients with resected stage III/IV melanoma treated with adjuvant pd-1 inhibitors: a national cohort study.
Christensen SK; Winther ML; Laursen IJ; Madsen FS; Brink C; Brix TH; Ellebaek E; Svane IM; Hansen FS; Haslund C; Laursen OK; Schmidt H; Larsen ID; Bastholt L; Ruhlmann CH
Support Care Cancer; 2024 Apr; 32(5):281. PubMed ID: 38598052
[TBL] [Abstract] [Full Text] [Related]
11. Molecular patterns of resistance to immune checkpoint blockade in melanoma.
Lauss M; Phung B; Borch TH; Harbst K; Kaminska K; Ebbesson A; Hedenfalk I; Yuan J; Nielsen K; Ingvar C; Carneiro A; Isaksson K; Pietras K; Svane IM; Donia M; Jönsson G
Nat Commun; 2024 Apr; 15(1):3075. PubMed ID: 38594286
[TBL] [Abstract] [Full Text] [Related]
12. Deciphering and overcoming Anti-pd-1 resistance in Melanoma: A comprehensive review of Mechanisms, biomarker Developments, and therapeutic strategies.
Wang R; Chen Y; Xie Y; Ma X; Liu Y
Int Immunopharmacol; 2024 May; 132():111989. PubMed ID: 38583243
[TBL] [Abstract] [Full Text] [Related]
13. Therapeutic inhibition of monocyte recruitment prevents checkpoint inhibitor-induced hepatitis.
Gudd CLC; Mitchell E; Atkinson SR; Mawhin MA; Turajlic S; Larkin J; Thursz MR; Goldin RD; Powell N; Antoniades CG; Woollard KJ; Possamai LA; Triantafyllou E
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38580334
[TBL] [Abstract] [Full Text] [Related]
14. Severe autoimmune hemolytic anemia following immunotherapy with checkpoint inhibitors in two patients with metastatic melanoma: a case report.
Fetter T; Fietz S; Bertlich M; Braegelmann C; de Vos-Hillebrand L; Wenzel J; Heine A; Landsberg J; Jansen P
Front Immunol; 2024; 15():1342845. PubMed ID: 38571955
[TBL] [Abstract] [Full Text] [Related]
15. Divergent local and systemic antitumor response in primary uveal melanomas.
Lucibello F; Lalanne AI; Le Gac AL; Soumare A; Aflaki S; Cyrta J; Dubreuil L; Mestdagh M; Salou M; Houy A; Ekwegbara C; Jamet C; Gardrat S; Le Ven A; Bernardeau K; Cassoux N; Matet A; Malaise D; Pierron G; Piperno-Neumann S; Stern MH; Rodrigues M; Lantz O
J Exp Med; 2024 Jun; 221(6):. PubMed ID: 38563818
[TBL] [Abstract] [Full Text] [Related]
16. The role of tissue-resident memory T cells as mediators for response and toxicity in immunotherapy-treated melanoma-two sides of the same coin?
Reschke R; Deitert B; Enk AH; Hassel JC
Front Immunol; 2024; 15():1385781. PubMed ID: 38562921
[TBL] [Abstract] [Full Text] [Related]
17. Efficiency and tolerance of second-line triple BRAF inhibitor/MEK inhibitor/anti-pd1 combined therapy in BRAF mutated melanoma patients with central nervous system metastases occurring during first-line combined targeted therapy: a real-life survey.
Fabre M; Lamoureux A; Meunier L; Samaran Q; Lesage C; Girard C; Du Thanh A; Moulis L; Dereure O
Melanoma Res; 2024 Jun; 34(3):241-247. PubMed ID: 38546723
[TBL] [Abstract] [Full Text] [Related]
18. Assessing the use of anti-pd1 monotherapy as adjuvant therapy and determinants of treatment choice in stage III cutaneous melanoma in the US.
Whitman ED; Totev TI; Jiang S; da Costa WL; Grebennik D; Wang H; Boca AE; Ayyagari R
BMC Cancer; 2024 Mar; 24(1):389. PubMed ID: 38539148
[TBL] [Abstract] [Full Text] [Related]
19. Treatments on the horizon for locally advanced basal cell carcinoma.
Idriss MH; Stull CM; Migden MR
Cancer Lett; 2024 May; 589():216821. PubMed ID: 38521198
[TBL] [Abstract] [Full Text] [Related]
20. B7-H3 is associated with the armored-cold phenotype and predicts poor immune checkpoint blockade response in melanoma.
Shen B; Mei J; Xu R; Cai Y; Wan M; Zhou J; Ding J; Zhu Y
Pathol Res Pract; 2024 Apr; 256():155267. PubMed ID: 38520953
[TBL] [Abstract] [Full Text] [Related]
[Next]
